MET and cancer: However, similar to most kinase-driven cancers, acquired resistance to MET-targeted therapy eventually arises by various mechanisms, including on-target resistance in kinase domain and off-target resistance by bypass signaling pathway activation, copy number alteration, and histologic transformation [19,20].